Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma

Wang, Wentao; Guo, Changyuan; Cui, Guanghui; Zhao, Song

doi:10.3748/wjg.v25.i37.5604

Cited by 18 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with our present observations, BC tumor samples showed elevated miR-21 expression, and miR-21 expression was transiently upregulated 8 h upon irradiation treatment in radio-resistant T47D cells, and its inhibition attenuated radiation resistance at cellular level [26]. miR-21 has been identified as an independent biomarker of the efficacy of radiotherapy and chemotherapy and thus can be adopted as an effective predictor of response to chemotherapy and radiotherapy in esophageal squamous cell carcinoma [27]. In agreement, the experimental data in our study indicated that miR-21 knock-in enhanced tolerance of BC cells to radiotherapy and promoted tumor immune escape.…”

Section: Discussionsupporting

confidence: 90%

Anti-PD-L1 Antibody Enhances T Cell Immune Responses and Reduces Resistance of Breast Cancer Cells to Radiotherapy

Guo

Ding

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Immune escape is a frequent occurrence, which limits the duration of antitumor immune responses to radiotherapy. Here, we aimed to ascertain the roles and underlying mechanisms of programmed death ligand 1 (PD-L1) in tolerance of breast cancer (BC) to radiotherapy. We first quantified microRNA-21 (miR-21) and PD-L1 expression in BC tissues and cells, followed by identification of the interactions between miR-21, PD-L1, and programmed cell death protein 4 (PDCD4). miR-21 knock-in mice were used to construct tumor-bearing models, which were then treated with anti-PD-L1 antibody and irradiation, followed by measurement of tumor growth and tumor immune escape. Finally, we evaluated the synergistic effects of radiotherapy and anti-PD-L1 antibody in vivo. The results showed increased miR-21 expression in BC tissues and cells, which was positively correlated with PD-L1 expression. The treatment with radiotherapy or anti-PD-L1 antibody in the miR-21 knock-in mice diminished tumor weight and volume, along with decreased CD3+CD8+ positive cells, serum IL-2 and IFN-γ levels, and lower PD-L1 expression, but augmented apoptosis of T and BC cells. Moreover, miR-21 significantly augmented PD-L1 expression via PI3K/Akt pathway activation by targeting PDCD4 in BC cells. Thus, radiotherapy and anti-PD-L1 antibody synergistically accelerated the therapeutic effect against BC in mice, thereby implicating a close interplay between radiotherapy, T cells, and the miR-21/PDCD4/PI3K/Akt/PD-L1 axis.

show abstract

Section: Discussionsupporting

confidence: 90%

Anti-PD-L1 Antibody Enhances T Cell Immune Responses and Reduces Resistance of Breast Cancer Cells to Radiotherapy

Guo

Ding

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…The incidence of ESCC has risen from 9th to 7th among all malignant tumors [ 18 ]. Although significant progress has been made in the treatment of ESCC, the prognosis of ESCC patients is still poor [ 19 ]. Therefore, it is important to identify ESCC-related biomarkers and explore the pathogenesis of ESCC.…”

Section: Discussionmentioning

confidence: 99%

FoXA2 promotes esophageal squamous cell carcinoma progression by ZEB2 activation

et al. 2021

View full text Add to dashboard Cite

Background It has been reported that Forkhead transcription family member (FOXA2) regulates esophageal squamous cell carcinoma (ESCC) progression. However, the specific mechanism, by which FOXA2 promotes ESCC malignant progression, remains unclear. Materials and methods QRT-PCR and western blotting were applied to measure FOXA2 expression in ESCC tissues, while CCK-8 assay and Transwell assays were used to investigate the effect of FOXA2 on ESCC. Luciferase reporter assay, followed by fast chromatin immunoprecipitation (ChIP) assay, was used to study the relationship between FOXA2 and ZEB2. Results FOXA2 was significantly increased in ESCC tissues, when compared to normal tissues. Moreover, high expression of FOXA2 was also found in ESCC cells. Knockdown of FOXA2 inhibited ESCC cell proliferation, invasion, and migration. Mechanically, FOXA2 was verified to regulate ZEB2 expression at transcription level. Moreover, ZEB2 reversed the inhibitory effect of FOXA2 on ESCC proliferation, invasion, and migration. The relationship between ZEB2 and FOXA2 in ESCC tissues was negative. Conclusions These results indicate that FOXA2 plays a critical role in ESCC progression and may become a potential candidate target for ESCC treatment.

show abstract

“…Moreover, recent studies have demonstrated that microRNAs play have great potential as biomarkers[ 30 , 35 , 36 ]. For example, low miR-335 expression is an independent prognostic factor and indicates a favorable prognosis in ESCA[ 37 ]; miR-1304 can be used as a powerful indicator for the diagnosis and recurrence of ESCA[ 38 ]; and miR-21 and miR-93 can be adopted as effective biomarkers for predicting radiotherapy and chemotherapy efficacy in ESCA[ 39 ]. Although some research has explored the diagnostic and prognostic roles in colorectal cancer, glioma, and lung cancer, the roles of miR-1269a in ESCA remain to be elucidated.…”

Section: Discussionmentioning

confidence: 99%

Development of a prognostic prediction model based on microRNA-1269a in esophageal cancer

Yu¹

2021

WJGO

View full text Add to dashboard Cite

BACKGROUND Esophageal cancer (ESCA) is a heterogeneous cancer with variable outcomes that are challenging to predict. MicroRNA (miR)-1269a is a newly discovered non-coding RNA that shows promising prognostic prediction in other cancers, but its clinical value in ESCA remains unclear. AIM To explore the relationship between miR-1269a and its clinical value and to develop a nomogram to succinctly display this relationship. METHODS We analyzed the expression of miR-1269a in 125 ESCA tissue samples with complete clinical data and 52 normal tissue samples. We determined the prognostic value of miR-1269a for overall survival (OS) and cancer-specific survival (CSS) and evaluated the association between miR-1269a and clinical variables including tumor location, histologic grade, metastatic stage, and American Joint Committee on Cancer (AJCC) stage using multivariate Cox analysis. Additionally, we developed a nomogram for OS and CSS based on miR-1269a expression using age and AJCC stage and assessed its prognostic performance. Using Gene Ontology and Kyoto Encyclopedia of Gene and Genomes analyses, we predicted the target genes of miR-1269a and analyzed their potential function in caner development. RESULTS The expression of miR-1269a was significantly higher in ESCA patients than healthy controls. Patients with high expression of miR-1269a showed poor prognosis in OS and CSS, suffered increased rates of low differentiation and metastasis, and exhibited tumor stage T3 + T4, positive lymph stage, and AJCC stage III + IV. The area under the receiver operating characteristic curve of miR-1269a was 0.716 for OS and 0.764 for CSS. Multivariate Cox analysis revealed that AJCC stage and miR-1269a were independent factors for OS and CSS. Combing with age, we constructed a nomogram for prognostic prediction. Additionally, our nomogram showed excellent predictive performance for OS and CSS after 3 years and 5 years and was easy to use. Ultimately, the functional analysis suggested that miR-1269a was mostly involved in the PI3K-AKT signaling pathway. CONCLUSION miR-1269a can be used as a potential indicator for the prognosis of ESCA patients. We developed an easy-to-use nomogram with excellent ESCA prognostic prediction for clinical use.

show abstract

Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma

Cited by 18 publications

References 32 publications

Anti-PD-L1 Antibody Enhances T Cell Immune Responses and Reduces Resistance of Breast Cancer Cells to Radiotherapy

Anti-PD-L1 Antibody Enhances T Cell Immune Responses and Reduces Resistance of Breast Cancer Cells to Radiotherapy

FoXA2 promotes esophageal squamous cell carcinoma progression by ZEB2 activation

Development of a prognostic prediction model based on microRNA-1269a in esophageal cancer

Contact Info

Product

Resources

About